{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:57:35Z","timestamp":1787871455807,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Sarcomas are rare, heterogeneous malignancies with over 100 subtypes and limited effective therapies in advanced stages. Theranostics, a strategy that combines diagnostic imaging and targeted radionuclide therapy using the same molecular target, has revolutionized care in cancers, including prostate and neuroendocrine tumors. This review evaluates the current evidence and future potential of theranostic applications in sarcoma. A comprehensive literature search was conducted across PubMed, Google Scholar, and clinicaltrials.gov for studies published between January 2010 and August 2025. Search terms included \u201ctheranostics,\u201d \u201cradionuclide,\u201d \u201cmolecular imaging,\u201d \u201csarcoma,\u201d and molecular targets such as PSMA, FAPI, SSTR, PDGFR, and TEM-1. Eligible articles included clinical trials, cohort studies, and systematic reviews. Case reports were included only when higher-level evidence was lacking. Key theranostic targets in sarcoma include FAP, PSMA, SSTR, and PDGFR. Among these, FAP-directed agents demonstrate the most clinical maturity, with improved diagnostic performance compared to 18F-FDG and early evidence of disease control with 90Y\/177Lu-labeled therapies. PSMA and SSTR expression in sarcomas is more variable and localized to tumor vasculature, with case-level therapeutic use and limited efficacy data. PDGFR and emerging targets, such as TEM-1, show biological promise but remain under investigation in early-phase studies. Theranostics represents a promising approach to individualized sarcoma treatment, with FAP-targeted agents showing the most advanced clinical development. FAP-based imaging improves lesion detection compared to standard 18F-FDG PET, and early therapeutic trials suggest disease control in select patients. However, broader validation and regulatory approval are needed before clinical integration. Theranostics represents a promising precision-medicine paradigm for sarcoma, linking diagnostic PET imaging with targeted radioligand therapy targeting a shared molecular target. With more than 100 histologic subtypes and limited effective treatment options in advanced disease, theranostics may provide a future therapeutic avenue for selected patients. Among currently investigated platforms, fibroblast activation protein-directed approaches are the most clinically advanced. 68Ga FAPI PET has demonstrated superior lesion detection compared with 18 F FDG across multiple sarcoma subtypes, and early studies of 90Y- and 177Lu-labeled FAPI agents report disease stabilization in selected patients with advanced disease, supporting biological and technical feasibility. In contemporary practice, FAP-directed imaging is best integrated within investigational frameworks to identify candidates for radioligand therapy, refine trial selection, and enable response monitoring in FAP-avid sarcomas. Other targets, including PSMA, SSTR, and PDGFR, remain exploratory and require prospective validation before clinical translation. Standard sarcoma management continues to rely on guideline-directed multimodality care, including surgery, radiation, and subtype-specific systemic therapy, with theranostic strategies currently limited to clinical trials or selected refractory settings. Broader clinical adoption will depend on prospective studies demonstrating meaningful clinical benefit, optimized dosimetry, and regulatory approval.<\/jats:p>","DOI":"10.1007\/s11864-026-01386-0","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:20:40Z","timestamp":1774538440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Theranostics in Sarcoma: A Critical Review of Current Evidence and Future Potential"],"prefix":"10.1007","volume":"27","author":[{"given":"Ojasvi","family":"Appana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Konieczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3322\/caac.21605","volume":"70","author":"AC Gamboa","year":"2020","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: An update on the current state of histiotype\u2010specific management in an era of personalized medicine. CA: Cancer J Clin. 2020;70:200\u201329. https:\/\/doi.org\/10.3322\/caac.21605.","journal-title":"CA: Cancer J Clin"},{"key":"1386_CR2","unstructured":"NCCN. Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma. 2024."},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, Miah AB, Dei Tos A, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, et al. Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:1348\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006.","journal-title":"Ann Oncol"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/edbk_205423","volume":"38","author":"D Katz","year":"2018","unstructured":"Katz D, Palmerini E, Pollack SM. More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments. Am Soc Clin Oncol Educ Book. 2018;38:925\u201338. https:\/\/doi.org\/10.1200\/edbk_205423.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA: Cancer J Clin. 2023;73:255\u201374. https:\/\/doi.org\/10.3322\/caac.21768.","journal-title":"CA: Cancer J Clin"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Sch\u00f6der H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19:534\u201350. https:\/\/doi.org\/10.1038\/s41571-022-00652-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/s1470-2045(19)30821-6","volume":"21","author":"K Herrmann","year":"2020","unstructured":"Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(19)30821-6.","journal-title":"Lancet Oncol"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/13543784.2024.2414119","volume":"33","author":"L Filippi","year":"2024","unstructured":"Filippi L, Ferrari C, Rubini G. Theranostic strategies in sarcoma: preliminary clinical evidence. Expert Opin Investig Drugs. 2024;33:1119\u201327. https:\/\/doi.org\/10.1080\/13543784.2024.2414119.","journal-title":"Expert Opin Investig Drugs"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.3390\/cancers13225744","volume":"13","author":"T Lindner","year":"2021","unstructured":"Lindner T, Giesel FL, Kratochwil C, Serfling SE. Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers. 2021;13:5744. https:\/\/doi.org\/10.3390\/cancers13225744.","journal-title":"Cancers"},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, Sun L, Lin Q, Chen H. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics. 2022;12:1557\u201369. https:\/\/doi.org\/10.7150\/thno.69475.","journal-title":"Theranostics"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, J\u00e4ger D, Flechsig P, Altmann A, et al. 68Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2018;60:386\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.215913.","journal-title":"J Nucl Med"},{"issue":"1","key":"1386_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2967\/jnumed.121.262096","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, et al. (68)Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the (68)Ga-FAPI PET Prospective Observational Trial. J Nucl Med. 2022;63(1):89\u201395.","journal-title":"J Nucl Med"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.123.267248","volume":"65","author":"H Lanzafame","year":"2024","unstructured":"Lanzafame H, Mavroeidi IA, Pabst KM, Desaulniers M, Ingenwerth M, Hirmas N, Kessler L, Nader M, Bartel T, Leyser S, et al. 68Ga-Fibroblast Activation Protein Inhibitor PET\/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy. J Nucl Med. 2024;65:880\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.267248.","journal-title":"J Nucl Med"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.semnuclmed.2024.01.001","volume":"54","author":"F Giammarile","year":"2024","unstructured":"Giammarile F, Knoll P, Paez D, Lobato EE, Ter\u00e1n AKC, Bolton RCD. Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine. Semin Nucl Med. 2024;54:340\u20134. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.01.001.","journal-title":"Semin Nucl Med"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.ccr-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM, Kessler L, Costa PF, Ferdinandus J, Weber M, Lippert M, Lueckerath K, Umutlu L, Kostbade K, et al. Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clin Cancer Res. 2022;28:4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-1432.","journal-title":"Clin Cancer Res"},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13139-025-00936-y","volume":"59","author":"M Abdulrahman","year":"2025","unstructured":"Abdulrahman M, Giesel F, Scott AM, Shi H, Zaidi H, Abdlkadir AS, Yaser S, Abuhijlih R, Al-Ibraheem A. Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review. Nucl Med Mol Imaging. 2025;59:289\u2013305. https:\/\/doi.org\/10.1007\/s13139-025-00936-y.","journal-title":"Nucl Med Mol Imaging"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"20220886","DOI":"10.1259\/bjr.20220886","volume":"96","author":"F Kleiburg","year":"2023","unstructured":"Kleiburg F, Heijmen L, Gelderblom H, Kielbasa SM, Bov\u00e9e JV, De Geus-Oei L-F. Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas. Br J Radiol. 2023;96:20220886. https:\/\/doi.org\/10.1259\/bjr.20220886.","journal-title":"Br J Radiol"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.18632\/oncotarget.13994","volume":"8","author":"B Heitk\u00f6tter","year":"2016","unstructured":"Heitk\u00f6tter B, Trautmann M, Gr\u00fcnewald I, B\u00f6gemann M, Rahbar K, Gevensleben H, Wardelmann E, Hartmann W, Steinestel K, Huss S. Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget. 2016;8:4268\u201376. https:\/\/doi.org\/10.18632\/oncotarget.13994.","journal-title":"Oncotarget"},{"issue":"2","key":"1386_CR19","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/RLU.0000000000002389","volume":"44","author":"V Militano","year":"2019","unstructured":"Militano V, Afaq A, Bomanji J. 68Ga-Prostate-Specific Membrane Antigen PET\/CT: Incidental Finding of a Liposarcoma. Clin Nucl Med. 2019;44(2):e90\u20132.","journal-title":"Clin Nucl Med"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1097\/rlu.0000000000003320","volume":"46","author":"C Can","year":"2020","unstructured":"Can C, G\u00fcndo\u011fan C, K\u00f6mek H. Is 68Ga\u2013Prostate-Specific Membrane Antigen PET\/CT Superior than 18F-FDG PET\/CT for Evaluation of Metastatic Osteosarcoma? Clin Nucl Med. 2020;46:e233\u20135. https:\/\/doi.org\/10.1097\/rlu.0000000000003320.","journal-title":"Clin Nucl Med"},{"key":"1386_CR21","doi-asserted-by":"publisher","first-page":"e005383","DOI":"10.1136\/jitc-2022-005383","volume":"10","author":"A Digklia","year":"2022","unstructured":"Digklia A, Boughdad S, Homicsko K, Dromain C, Trimech M, Dolcan A, Peters S, Prior J, Schaefer N. First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer. J Immunother Cancer. 2022;10:e005383. https:\/\/doi.org\/10.1136\/jitc-2022-005383.","journal-title":"J Immunother Cancer"},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/a-0914-2486","volume":"58","author":"M J\u00fcptner","year":"2019","unstructured":"J\u00fcptner M, Marx M, Zuhayra M, L\u00fctzen U. Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. Nukl. 2019;58:328\u201330. https:\/\/doi.org\/10.1055\/a-0914-2486.","journal-title":"Nukl"},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"1220586","DOI":"10.3389\/fonc.2023.1220586","volume":"13","author":"JH Wang","year":"2023","unstructured":"Wang JH, Kiess AP. PSMA-targeted therapy for non-prostate cancers. Front Oncol. 2023;13:1220586. https:\/\/doi.org\/10.3389\/fonc.2023.1220586.","journal-title":"Front Oncol"},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1007\/s00259-025-07224-z","volume":"52","author":"F Kleiburg","year":"2025","unstructured":"Kleiburg F, van der Hulle T, Gelderblom H, Slingerland M, Speetjens FM, Hawinkels LJ, Dibbets-Schneider P, van Velden FH, Pool M, Lam SW, et al. PSMA expression and PSMA PET\/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study. Eur J Nucl Med. 2025;52:3690\u20139. https:\/\/doi.org\/10.1007\/s00259-025-07224-z.","journal-title":"Eur J Nucl Med"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","volume":"62","author":"SY Park","year":"2021","unstructured":"Park SY, Parihar AS, Bodei L, Hope TA, Mallak N, Millo C, Prasad K, Wilson D, Zukotynski K, Mittra E. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects. J Nucl Med. 2021;62:1323\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.251512.","journal-title":"J Nucl Med"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s13139-024-00854-5","volume":"58","author":"SA Han","year":"2024","unstructured":"Han SA, Ryu J, Song SW, Kim J-S, Ryu J-S, Oh M. 68Ga-DOATATOC Brain PET\/CT Imaging in a case of Dural Metastasis from Synovial Sarcoma. Nucl Med Mol Imaging. 2024;58:310\u20136. https:\/\/doi.org\/10.1007\/s13139-024-00854-5.","journal-title":"Nucl Med Mol Imaging"},{"key":"1386_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/rlu.0000000000001288","volume":"41","author":"A Crespo-Jara","year":"2016","unstructured":"Crespo-Jara A, Manzano RG, Sierra ML, Pe\u00f1a MCR, Masllorens AB. A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs. Clin Nucl Med. 2016;41:705\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000001288.","journal-title":"Clin Nucl Med"},{"key":"1386_CR28","unstructured":"Tinoco G. 68Ga-DOTATATE PET\/CT for the Diagnosis of Soft Tissue Sarcomas. NCT06500065. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06500065. Accessed 23 Sept 2025."},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.esmoop.2020.100037","volume":"6","author":"M Brahmi","year":"2021","unstructured":"Brahmi M, Lesluyes T, Dufresne A, Toulmonde M, Italiano A, Mir O, Le Cesne A, Valentin T, Chevreau C, Bonvalot S, et al. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. ESMO Open. 2021;6:100037. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100037.","journal-title":"ESMO Open"},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/cpaa.s130178","volume":"9","author":"A Pender","year":"2017","unstructured":"Pender A, Jones RL. Olaratumab: a platelet-derived growth factor receptor-\u03b1-blocking antibody for the treatment of soft tissue sarcoma. Clin Pharmacol Adv Appl. 2017;9:159\u201364. . https:\/\/doi.org\/10.2147\/cpaa.s130178","journal-title":"Clin Pharmacol Adv Appl"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/s0140-6736(16)30587-6","volume":"388","author":"WD Tap","year":"2016","unstructured":"Tap WD, Jones RL, Van Tine A, Chmielowski B, Elias B, Adkins AD, Agulnik D, Cooney M, Livingston MM, Pennock MB. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488\u201397. https:\/\/doi.org\/10.1016\/s0140-6736(16)30587-6.","journal-title":"Lancet"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.esmoop.2020.100037","volume":"6","author":"M Brahmi","year":"2021","unstructured":"Brahmi M, Lesluyes T, Dufresne A, Toulmonde M, Italiano A, Mir O, Le Cesne A, Valentin T, Chevreau C, Bonvalot S, et al. Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. ESMO Open. 2021;6:100037. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100037.","journal-title":"ESMO Open"},{"key":"1386_CR33","unstructured":"Telix Pharmaceuticals. An Open-label. Phase 1 Study to Assess Safety, Tolerability, Dosimetry, Pharmacokinetics and Imaging Properties of 89Zr-olaratumab (89Zr-TLX300-CDx) in Participants With Soft Tissue Sarcoma. 2024."},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2967\/jnumed.121.262468","volume":"63","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, Bauer S, Schuler M, Ahrens M, Schildhaus H-U, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. J Nucl Med. 2021;63:727\u201334. https:\/\/doi.org\/10.2967\/jnumed.121.262468.","journal-title":"J Nucl Med"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Shahrnoy AA, Nami R, Mazidi SM, Nasiri M. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med. 2024;52:237\u201346. https:\/\/doi.org\/10.1007\/s00259-024-06795-7.","journal-title":"Eur J Nucl Med"},{"key":"1386_CR36","unstructured":"Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach. 2022."},{"issue":"12","key":"1386_CR37","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.2967\/jnumed.122.264827","volume":"64","author":"L Kessler","year":"2023","unstructured":"Kessler L, et al. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial. J Nucl Med. 2023;64(12):1910\u20137.","journal-title":"J Nucl Med"},{"key":"1386_CR38","unstructured":"FDA approves lutetium Lu. 177 dotatate for pediatric patients 12 years and older with GEP-NETS. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets. Accessed 23 Sept 2025."},{"key":"1386_CR39","unstructured":"FDA approves Pluvicto for metastatic castration-resistant prostate cance. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed 23 Sept 2025."},{"key":"1386_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cpet.2021.03.008","volume":"16","author":"S Katal","year":"2021","unstructured":"Katal S, Maldonado A, Carrascoso J, Assadi M, Gholamrezanezhad A. Theranostic Agents in Musculoskeletal Disorders. PET Clin. 2021;16:441\u20138. https:\/\/doi.org\/10.1016\/j.cpet.2021.03.008.","journal-title":"PET Clin"},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2017.10.035","volume":"90","author":"Y Guo","year":"2018","unstructured":"Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, et al. Tumour endothelial marker 1\/endosialin-mediated targeting of human sarcoma. Eur J Cancer. 2018;90:111\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.035.","journal-title":"Eur J Cancer"},{"key":"1386_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/cbt.27825","volume":"15","author":"C Li","year":"2014","unstructured":"Li C, Chacko A-M, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, et al. Antibody-based tumor vascular theranostics targeting endosialin\/TEM1 in a new mouse tumor vascular model. Cancer Biol Ther. 2014;15:443\u201351. https:\/\/doi.org\/10.4161\/cbt.27825.","journal-title":"Cancer Biol Ther"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01386-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01386-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:38Z","timestamp":1781643398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01386-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01386-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the author(s) used Grammarly in order to improve orthography and readability. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of Generative AI and AI-Assisted Technologies in the Manuscript Preparation Process"}}],"article-number":"18"}}